Pharmacological management of agitation in dementia: An evidence-based review with expert consensus.

J Chin Med Assoc · 2026 · PMC13004216 · PMID 41527161

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

However, the Study of Mirtazapine for Agitated Behaviors in Dementia (SYMBAD) trial (n = 204) found no significant benefit over placebo for agitation in AD and noted a nonsignificant trend toward higher mortality at 16 weeks. 70 Caution is advised when prescribing mirtazapine for this indication.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.